‘We are Questioning the Timing of Last Month’s Upgrade’

‘We are Questioning the Timing of Last Month’s Upgrade’

@...@The FDA*s revised labelling following 26 cases of alleged Viekira Pak and Technivie related serious liver disease and death will likely materially negatively ©impact AbbVie positon in this high profitability, short duration but competitive segment…

@...@We are lowering the PT on ABBV from $60 to $56// Our rating remains neutral// We have lowered our HCV franchise forecasts by 60% in 2016~ 2020 associated with unfavourable re~labeling following 24 reported cases of severe liver disease and death© in cirrhotic patients with decompensated liver disease//